Announcement • Apr 29
Beijing Scitop Bio-tech Co., Ltd., Annual General Meeting, May 20, 2026 Beijing Scitop Bio-tech Co., Ltd., Annual General Meeting, May 20, 2026, at 14:30 China Standard Time. Location: The Company's Meeting Room, Beijing China Valuation Update With 7 Day Price Move • Apr 28
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to CN¥18.79, the stock trades at a trailing P/E ratio of 55.5x. Average trailing P/E is 34x in the Food industry in China. Total returns to shareholders of 8.4% over the past three years. Reported Earnings • Apr 22
First quarter 2026 earnings released: EPS: CN¥0.06 (vs CN¥0.08 in 1Q 2025) First quarter 2026 results: EPS: CN¥0.06 (down from CN¥0.08 in 1Q 2025). Revenue: CN¥85.0m (up 9.5% from 1Q 2025). Net income: CN¥15.0m (down 27% from 1Q 2025). Profit margin: 18% (down from 26% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings. New Risk • Apr 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 2.4% per year over the past 5 years. High level of non-cash earnings (30% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.6% average weekly change). Valuation Update With 7 Day Price Move • Apr 14
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥21.30, the stock trades at a trailing P/E ratio of 56.5x. Average trailing P/E is 33x in the Food industry in China. Total loss to shareholders of 4.5% over the past three years. Announcement • Mar 31
Beijing Scitop Bio-tech Co., Ltd. to Report Q1, 2026 Results on Apr 22, 2026 Beijing Scitop Bio-tech Co., Ltd. announced that they will report Q1, 2026 results on Apr 22, 2026 Valuation Update With 7 Day Price Move • Mar 27
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥18.19, the stock trades at a trailing P/E ratio of 48.2x. Average trailing P/E is 32x in the Food industry in China. Total loss to shareholders of 21% over the past three years. Announcement • Dec 31
Beijing Scitop Bio-tech Co., Ltd. to Report Fiscal Year 2025 Results on Apr 22, 2026 Beijing Scitop Bio-tech Co., Ltd. announced that they will report fiscal year 2025 results on Apr 22, 2026 Valuation Update With 7 Day Price Move • Nov 14
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥19.90, the stock trades at a trailing P/E ratio of 52.8x. Average forward P/E is 21x in the Food industry in China. Total returns to shareholders of 1.6% over the past three years. Reported Earnings • Oct 22
Third quarter 2025 earnings released: EPS: CN¥0.13 (vs CN¥0.099 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.13 (up from CN¥0.099 in 3Q 2024). Revenue: CN¥104.0m (up 29% from 3Q 2024). Net income: CN¥35.0m (up 27% from 3Q 2024). Profit margin: 34% (in line with 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Announcement • Sep 30
Beijing Scitop Bio-tech Co., Ltd. to Report Q3, 2025 Results on Oct 22, 2025 Beijing Scitop Bio-tech Co., Ltd. announced that they will report Q3, 2025 results on Oct 22, 2025 Reported Earnings • Aug 21
Second quarter 2025 earnings released: EPS: CN¥0.08 (vs CN¥0.10 in 2Q 2024) Second quarter 2025 results: EPS: CN¥0.08 (down from CN¥0.10 in 2Q 2024). Revenue: CN¥85.7m (up 8.5% from 2Q 2024). Net income: CN¥20.9m (down 17% from 2Q 2024). Profit margin: 24% (down from 32% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Aug 01
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥20.40, the stock trades at a trailing P/E ratio of 55.9x. Average forward P/E is 20x in the Food industry in China. Total returns to shareholders of 19% over the past three years. Declared Dividend • Jul 14
Dividend of CN¥0.15 announced Dividend of CN¥0.15 is the same as last year. Ex-date: 16th July 2025 Payment date: 16th July 2025 Dividend yield will be 0.9%, which is lower than the industry average of 2.2%. Sustainability & Growth Dividend is covered by earnings (40% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 46 years, indicating a lack of growth and stability in payments. The company's earnings per share (EPS) would need to decline by 55% to shift the payout ratio to a potentially unsustainable range, which is more than the 8.6% EPS decline seen over the last 5 years. Valuation Update With 7 Day Price Move • Jul 04
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to CN¥18.76, the stock trades at a trailing P/E ratio of 51.4x. Average forward P/E is 21x in the Food industry in China. Total returns to shareholders of 13% over the past three years. Announcement • Jul 02
Beijing Scitop Bio-tech Co., Ltd. to Report First Half, 2025 Results on Aug 20, 2025 Beijing Scitop Bio-tech Co., Ltd. announced that they will report first half, 2025 results on Aug 20, 2025 Valuation Update With 7 Day Price Move • May 27
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥17.59, the stock trades at a trailing P/E ratio of 48.2x. Average forward P/E is 20x in the Food industry in China. Total returns to shareholders of 16% over the past three years. New Risk • May 25
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 1.0% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.4% average weekly change). Announcement • Apr 25
Beijing Scitop Bio-Tech Co., Ltd. Proposes Final Cash Dividend for the Year 2024 Beijing Scitop Bio-tech Co., Ltd. announced on 23 April 2025 the profit distribution proposal for 2024: final Cash dividend of CNY 1.50000000 per 10 shares (tax included). Reported Earnings • Apr 24
First quarter 2025 earnings released: EPS: CN¥0.08 (vs CN¥0.07 in 1Q 2024) First quarter 2025 results: EPS: CN¥0.08 (up from CN¥0.07 in 1Q 2024). Revenue: CN¥77.6m (up 32% from 1Q 2024). Net income: CN¥20.3m (up 9.8% from 1Q 2024). Profit margin: 26% (down from 31% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. New Risk • Apr 24
New major risk - Revenue and earnings growth Earnings have declined by 1.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 1.0% per year over the past 5 years. Minor Risk Paying a dividend despite having no free cash flows. Announcement • Apr 23
Beijing Scitop Bio-tech Co., Ltd., Annual General Meeting, May 21, 2025 Beijing Scitop Bio-tech Co., Ltd., Annual General Meeting, May 21, 2025, at 14:30 China Standard Time. Location: The Company's Meeting Room, Beijing China Valuation Update With 7 Day Price Move • Apr 14
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to CN¥13.55, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 19x in the Food industry in China. Total loss to shareholders of 23% over the past three years. Announcement • Mar 31
Beijing Scitop Bio-tech Co., Ltd. to Report Q1, 2025 Results on Apr 23, 2025 Beijing Scitop Bio-tech Co., Ltd. announced that they will report Q1, 2025 results on Apr 23, 2025 Announcement • Dec 31
Beijing Scitop Bio-tech Co., Ltd. to Report Fiscal Year 2024 Results on Apr 23, 2025 Beijing Scitop Bio-tech Co., Ltd. announced that they will report fiscal year 2024 results on Apr 23, 2025 Reported Earnings • Oct 30
Third quarter 2024 earnings released: EPS: CN¥0.099 (vs CN¥0.12 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.099 (down from CN¥0.12 in 3Q 2023). Revenue: CN¥80.7m (up 4.7% from 3Q 2023). Net income: CN¥27.7m (down 13% from 3Q 2023). Profit margin: 34% (down from 41% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 36% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Food industry in China. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Board Change • Oct 24
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Fei Lu was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to CN¥14.77, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 17x in the Food industry in China. Total loss to shareholders of 12% over the past three years. Announcement • Sep 30
Beijing Scitop Bio-tech Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024 Beijing Scitop Bio-tech Co., Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024 Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 26% After last week's 26% share price gain to CN¥17.02, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 17x in the Food industry in China. Total loss to shareholders of 4.1% over the past three years. Reported Earnings • Aug 21
Second quarter 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.077 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.10 (up from CN¥0.077 in 2Q 2023). Revenue: CN¥79.0m (up 17% from 2Q 2023). Net income: CN¥25.0m (up 23% from 2Q 2023). Profit margin: 32% (up from 30% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 33% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Food industry in China. Over the last 3 years on average, earnings per share has fallen by 12% per year whereas the company’s share price has fallen by 15% per year. Announcement • Jun 29
Beijing Scitop Bio-tech Co., Ltd. to Report First Half, 2024 Results on Aug 21, 2024 Beijing Scitop Bio-tech Co., Ltd. announced that they will report first half, 2024 results on Aug 21, 2024 Declared Dividend • Jun 28
Dividend of CN¥0.15 announced Shareholders will receive a dividend of CN¥0.15. Ex-date: 3rd July 2024 Payment date: 3rd July 2024 Dividend yield will be 1.0%, which is lower than the industry average of 2.2%. Sustainability & Growth Dividend is covered by earnings (44% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 36 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 34% over the next year, which should provide support to the dividend and adequate earnings cover. Announcement • Jun 27
Beijing Scitop Bio-Tech Co., Ltd. Announces Cash Dividend on Share A for the Year 2023, Payable on July 3, 2024 Beijing Scitop Bio-tech Co., Ltd. announced Cash dividend/10 shares (tax included): CNY 1.50000000 on share A for the year 2023. Record date: 02 July 2024, Ex-date: 03 July 2024 and Payment date: 03 July 2024. Announcement • Apr 27
Beijing Scitop Bio-Tech Co., Ltd. Proposes Final Dividend for the Year 2023 Beijing Scitop Bio-tech Co., Ltd. proposed final cash dividend/10 shares (tax included) of CNY 1.50000000 for 2023. Announcement • Apr 26
Beijing Scitop Bio-tech Co., Ltd., Annual General Meeting, May 16, 2024 Beijing Scitop Bio-tech Co., Ltd., Annual General Meeting, May 16, 2024, at 14:30 China Standard Time. Location: The Company's Meeting Room, Beijing China Reported Earnings • Apr 25
First quarter 2024 earnings released: EPS: CN¥0.07 (vs CN¥0.073 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.07 (down from CN¥0.073 in 1Q 2023). Revenue: CN¥59.0m (down 18% from 1Q 2023). Net income: CN¥18.5m (down 7.7% from 1Q 2023). Profit margin: 31% (up from 28% in 1Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 8% per year. Valuation Update With 7 Day Price Move • Apr 18
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to CN¥14.55, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 19x in the Food industry in China. Total loss to shareholders of 31% over the past three years. Announcement • Mar 30
Beijing Scitop Bio-tech Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024 Beijing Scitop Bio-tech Co., Ltd. announced that they will report Q1, 2024 results on Apr 25, 2024 Announcement • Dec 29
Beijing Scitop Bio-tech Co., Ltd. to Report Fiscal Year 2023 Results on Apr 25, 2024 Beijing Scitop Bio-tech Co., Ltd. announced that they will report fiscal year 2023 results on Apr 25, 2024 Reported Earnings • Oct 25
Third quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.19 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.12 (down from CN¥0.19 in 3Q 2022). Revenue: CN¥77.0m (down 28% from 3Q 2022). Net income: CN¥31.7m (down 24% from 3Q 2022). Profit margin: 41% (up from 39% in 3Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 38% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Food industry in China. Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 6% per year. Announcement • Sep 30
Beijing Scitop Bio-tech Co., Ltd. to Report Q3, 2023 Results on Oct 25, 2023 Beijing Scitop Bio-tech Co., Ltd. announced that they will report Q3, 2023 results on Oct 25, 2023 New Risk • Aug 06
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 27% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (27% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Shareholders have been diluted in the past year (18% increase in shares outstanding). Reported Earnings • Aug 02
Second quarter 2023 earnings released: EPS: CN¥0.077 (vs CN¥0.094 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.077 (down from CN¥0.094 in 2Q 2022). Revenue: CN¥67.8m (down 4.2% from 2Q 2022). Net income: CN¥20.3m (down 5.1% from 2Q 2022). Profit margin: 30% (in line with 2Q 2022). Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Food industry in China. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 12% per year, which means it is performing significantly worse than earnings. Announcement • Jul 01
Beijing Scitop Bio-tech Co., Ltd. to Report First Half, 2023 Results on Aug 02, 2023 Beijing Scitop Bio-tech Co., Ltd. announced that they will report first half, 2023 results on Aug 02, 2023 Valuation Update With 7 Day Price Move • Jun 29
Investor sentiment deteriorates as stock falls 33% After last week's 33% share price decline to CN¥16.31, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 23x in the Food industry in China. Total loss to shareholders of 39% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥9.00 per share. Announcement • Jun 23
Beijing Scitop Bio-Tech Co., Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date Is 30 June 2023 Beijing Scitop Bio-tech Co., Ltd. announced 2022 final profit distribution plan to be implemented (A shares): Cash dividend/10 shares (tax included) of CNY 3.00000000. Record date is 29 June 2023. Ex-date is 30 June 2023. Payment date is 30 June 2023. Valuation Update With 7 Day Price Move • Apr 25
Investor sentiment deteriorates as stock falls 24% After last week's 24% share price decline to CN¥26.38, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 25x in the Food industry in China. Total returns to shareholders of 20% over the past year. Reported Earnings • Apr 19
First quarter 2023 earnings released: EPS: CN¥0.11 (vs CN¥0.16 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.11 (down from CN¥0.16 in 1Q 2022). Revenue: CN¥72.1m (down 16% from 1Q 2022). Net income: CN¥20.1m (down 14% from 1Q 2022). Profit margin: 28% (in line with 1Q 2022). Revenue is forecast to grow 32% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Food industry in China. Valuation Update With 7 Day Price Move • Jan 03
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥33.26, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 25x in the Food industry in China. Negligible returns to shareholders over past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥29.48 per share. Valuation Update With 7 Day Price Move • Dec 08
Investor sentiment deteriorated over the past week After last week's 22% share price decline to CN¥23.87, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 26x in the Food industry in China. Total loss to shareholders of 22% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥29.48 per share. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Oct 28
Third quarter 2022 earnings released: EPS: CN¥0.28 (vs CN¥0.27 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.28 (up from CN¥0.27 in 3Q 2021). Revenue: CN¥107.2m (up 6.2% from 3Q 2021). Net income: CN¥41.8m (up 4.0% from 3Q 2021). Profit margin: 39% (in line with 3Q 2021). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Food industry in China. Reported Earnings • Aug 26
Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.16 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.14 (down from CN¥0.16 in 2Q 2021). Revenue: CN¥70.8m (down 18% from 2Q 2021). Net income: CN¥21.4m (down 7.2% from 2Q 2021). Profit margin: 30% (up from 27% in 2Q 2021). The increase in margin was driven by lower expenses. Over the next year, revenue is forecast to grow 42%, compared to a 23% growth forecast for the Food industry in China. Announcement • Jun 23
Beijing Scitop Bio-Tech Co., Ltd. Announces Final Cash Dividend on A Shares for 2021, Payable on 29 June 2022 Beijing Scitop Bio-tech Co., Ltd. announced final cash dividend of CNY 5.00000000 per 10 shares on A shares for 2021. Record date is 28 June 2022, Ex-date is 29 June 2022 and Payment date is 29 June 2022. Announcement • May 20
Beijing Scitop Bio-Tech Co., Ltd. Approves Final Cash Dividend for the Year 2021 Beijing Scitop Bio-tech Co., Ltd. approved final cash dividend of CNY 5.00000000 per 10 shares (tax included) for the year 2021, at its Annual General Meeting of 2021 on 18 May 2022. Announcement • Apr 27
Beijing Scitop Bio-Tech Co., Ltd. Announces Profit Distribution Proposal for 2021 Beijing Scitop Bio-tech Co., Ltd. announced on 26 April 2022 the profit distribution proposal for 2021 as follows: Cash dividend/10 shares (tax included) of CNY 5.00000000. Reported Earnings • Apr 27
First quarter 2022 earnings: EPS and revenues miss analyst expectations First quarter 2022 results: EPS: CN¥0.16 (up from CN¥0.14 in 1Q 2021). Revenue: CN¥86.1m (up 6.6% from 1Q 2021). Net income: CN¥23.4m (up 8.8% from 1Q 2021). Profit margin: 27% (in line with 1Q 2021). Revenue missed analyst estimates by 11%. Earnings per share (EPS) also missed analyst estimates by 11%. Over the next year, revenue is forecast to grow 44%, compared to a 17% growth forecast for the industry in China. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Jan 21
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥34.72, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 28x in the Food industry in China. Total returns to shareholders of 2.2% over the past year. Valuation Update With 7 Day Price Move • Dec 27
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥34.84, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 30x in the Food industry in China. Total returns to shareholders of 7.1% over the past year. Reported Earnings • Oct 28
Third quarter 2021 earnings released: EPS CN¥0.27 (vs CN¥0.25 in 3Q 2020) The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2021 results: Revenue: CN¥101.0m (down 2.6% from 3Q 2020). Net income: CN¥40.2m (up 19% from 3Q 2020). Profit margin: 40% (up from 33% in 3Q 2020). The increase in margin was driven by lower expenses. Valuation Update With 7 Day Price Move • Sep 17
Investor sentiment deteriorated over the past week After last week's 18% share price decline to CN¥26.60, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 26x in the Food industry in China. Total loss to shareholders of 35% over the past year. Reported Earnings • Aug 18
Second quarter 2021 earnings released: EPS CN¥1.45 (vs CN¥0.21 in 2Q 2020) The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥86.6m (up 7.2% from 2Q 2020). Net income: CN¥23.0m (down 2.1% from 2Q 2020). Profit margin: 27% (down from 29% in 2Q 2020). The decrease in margin was driven by higher expenses. Valuation Update With 7 Day Price Move • May 20
Investor sentiment improved over the past week After last week's 21% share price gain to CN¥68.63, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 28x in the Food industry in China. Reported Earnings • Apr 25
First quarter 2021 earnings released: EPS CN¥0.26 (vs CN¥0.24 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥80.7m (up 36% from 1Q 2020). Net income: CN¥21.6m (up 43% from 1Q 2020). Profit margin: 27% (up from 25% in 1Q 2020). The increase in margin was driven by higher revenue. Is New 90 Day High Low • Feb 24
New 90-day low: CN¥55.19 The company is down 8.0% from its price of CN¥59.77 on 26 November 2020. The Chinese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Food industry, which is up 21% over the same period. Is New 90 Day High Low • Jan 28
New 90-day low: CN¥58.10 The company is down 12% from its price of CN¥65.90 on 30 October 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Food industry, which is up 21% over the same period. Valuation Update With 7 Day Price Move • Dec 28
Investor sentiment deteriorated over the past week After last week's 17% share price decline to CN¥59.35, the stock is trading at a trailing P/E ratio of 39.4x, down from the previous P/E ratio of 47.4x. This compares to an average P/E of 38x in the Food industry in China. Is New 90 Day High Low • Dec 16
New 90-day high: CN¥76.29 The company is up 6.0% from its price of CN¥72.24 on 17 September 2020. The Chinese market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Food industry, which is up 2.0% over the same period. Valuation Update With 7 Day Price Move • Dec 04
Market bids up stock over the past week After last week's 25% share price gain to CN¥72.95, the stock is trading at a trailing P/E ratio of 48.4x, up from the previous P/E ratio of 38.9x. This compares to an average P/E of 39x in the Chemicals industry in China. Is New 90 Day High Low • Nov 27
New 90-day low: CN¥58.58 The company is down 31% from its price of CN¥84.85 on 28 August 2020. The Chinese market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 5.0% over the same period. Is New 90 Day High Low • Nov 04
New 90-day low: CN¥61.49 The company is down 16% from its price of CN¥73.16 on 06 August 2020. The Chinese market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is down 3.0% over the same period. Reported Earnings • Oct 29
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥98.6m, up 7.6% from the prior year. Total revenue was CN¥333.7m over the last 12 months, up 8.9% from the prior year.